-+ 0.00%
-+ 0.00%
-+ 0.00%

Microchip Biotech (688321.SH): NW001 clinical trial application for injection accepted

Zhitongcaijing·08/05/2026 13:25:11
Listen to the news

Zhitong Finance App News, Microchip Biotech (688321.SH) issued an announcement. The company recently received the “Notice of Acceptance” issued by the Drug Evaluation Center of the State Drug Administration for registered clinical trials of domestically produced drugs. The clinical trial application for injectable NW001 developed by the company in cooperation with Chengdu Microchip Xinyu Biotechnology Co., Ltd. to treat advanced malignant tumors (solid tumors and lymphoma) was accepted.

NW001 is an epigenetic immune-modulatingantibody conjugate (EIMAC, Epigenetic Immune-ModulatingAntibody Conjugate). The NW001 antibody is partly a humanized PD-L1 monoclonal antibody and combines a new and improved HDACi load through a unique design. After NW001 binds to PD-L1 on the cell surface, it undergoes endocytosis, cleaves and releases highly active small molecule HDACi loading within the cell, exhibiting comprehensive anti-tumor activity of apparent immunity.